Analyzing...
Loading company...
Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 6,847 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. The company serves the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,739 Cr revenue.
COGS 24.6%, employees 29.6%.
“We expect to close the full year with a decline in revenue in the range of 3% to 5% with operating EBITDA margin in the end of 22% to 23%.”
“three to 5% Yes.”
“maintaining our full year guidance.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 6.5%▼ | 10.3% |
| ROCE | 8.3%▼ | 13.7% |
| Net Margin | 8.3%▲ | 7.6% |
| EBITDA Margin | 24.0%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
| Rev Growth 3yr | 5.3%▼ | 10.0% |
| EPS Growth 3yr | -12.1%▼ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,739 Cr +2.6% | ₹3,642 Cr +4.4% | ₹3,489 Cr +9.3% | ₹3,193 Cr +22.6% | ₹2,604 Cr +19.2% | ₹2,184 Cr +8.6% | ₹2,012 Cr +10.2% | ₹1,826 Cr |
| Other Income | ₹71 Cr -1.5% | ₹72 Cr -20.8% | ₹91 Cr +27.8% | ₹71 Cr +34.3% | ₹53 Cr -18.3% | ₹65 Cr -20.8% | ₹82 Cr +8.7% | ₹75 Cr |
| Total Income | ₹3,809 Cr +2.6% | ₹3,714 Cr +3.8% | ₹3,579 Cr +9.7% | ₹3,264 Cr +22.8% | ₹2,657 Cr +18.1% | ₹2,249 Cr +7.4% | ₹2,094 Cr +10.1% | ₹1,901 Cr |
| COGS | ₹919 Cr -2.5% | ₹943 Cr +1.3% | ₹930 Cr +8.1% | ₹860 Cr +14.8% | ₹749 Cr +42.3% | ₹527 Cr +1.4% | ₹519 Cr -2.2% | ₹531 Cr |
| ₹3,322 Cr +7.6% | ₹3,086 Cr +4.7% | ₹2,947 Cr +10.4% | ₹2,670 Cr +24.7% | ₹2,142 Cr +18.0% | ₹1,815 Cr +10.1% | ₹1,648 Cr +10.9% | ₹1,485 Cr | |
| Profit Before Tax | ₹411 Cr -37.7% | ₹660 Cr +6.3% | ₹621 Cr +4.6% | ₹594 Cr +22.5% | ₹484 Cr +3.2% | ₹469 Cr -9.2% | ₹517 Cr +24.4% | ₹415 Cr |
| Exceptional Items | (₹77 Cr) ↓ Decline | ₹32 Cr ↑ Recovery | (₹11 Cr) | ₹0.00 Cr +100.0% | (₹31 Cr) ↓ Decline | ₹35 Cr -50.9% | ₹71 Cr | ₹0.00 Cr |
| ₹94 Cr -42.5% | ₹164 Cr +47.7% | ₹111 Cr -14.2% | ₹129 Cr +45.8% | ₹89 Cr +37.8% | ₹64 Cr -38.6% | ₹105 Cr +25.1% | ₹84 Cr | |
| Net Profit | ₹317 Cr -36.2% | ₹496 Cr -2.7% | ₹510 Cr +9.8% | ₹464 Cr +17.3% | ₹396 Cr -2.2% | ₹405 Cr -1.7% | ₹412 Cr +24.3% | ₹332 Cr |
| Profit (Owners) | ₹317 Cr -36.2% | ₹496 Cr -2.7% | ₹510 Cr +9.8% | ₹464 Cr +17.3% | ₹396 Cr -2.2% | ₹405 Cr -1.7% | ₹412 Cr +24.3% | ₹332 Cr |
| Other Comprehensive Income | (₹196 Cr) | (₹15 Cr) ↓ Decline | ₹143 Cr ↑ Recovery | (₹97 Cr) ↓ Decline | ₹43 Cr -77.3% | ₹191 Cr ↑ Recovery | (₹192 Cr) -172.9% | (₹70 Cr) |
| EPS | ₹7.86 | ₹12.33 | ₹12.69 | ₹11.57 | ₹9.88 | ₹10.12 | ₹10.30 | ₹8.29 |
| Diluted Shares | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr | ₹40 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Syngene International Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 29, 2026. Further, the company has informed the Exchange regarding voting res...
Syngene International Limited has informed the Exchange about Link of Recording
Syngene International Limited has informed the Exchange about Copy of Newspaper Publication
Syngene International Limited has informed the Exchange about Investor Presentation
Syngene International Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 29, 2026
Syngene International Limited has informed the Exchange about Resignation of Director/KMP/SMP
Syngene International Limited has informed the Exchange regarding Resignation of Mr Kush Parmar as Independent Director of the company w.e.f. July 29, 2026.
Syngene International Limited has informed the Exchange regarding a press release dated July 29, 2026, titled "Q1 FY27 revenue from operations at Rs. 736 Cr; Operating EBITDA at Rs. 91 Cr".
Syngene International Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Syngene International Limited has informed the Exchange about Schedule of meet
Syngene International Limited has informed the Exchange about change in Management
Syngene International Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Syngene International Limited has informed the Exchange about Resignation of Statutory Auditor
Syngene International Limited has informed the Exchange regarding Resignation of M/s B S R & Co. LLP, Statutory Auditor of material subsidiary of the company w.e.f. July 07, 2026.
Syngene International Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company